[en] Tumor angiogenesis is one of the most important fields of cancer research. It is important to identify the putative targets for antiangiogenic strategies. To date, a number of angiogenic agents have been identified: bFGF, the different VEGF isoforms, integrins, proteases (matrix metalloproteases and serine proteases),... Furthermore, several physiological anti-angiogenic agents have been isolated such as endostatin, angiostatin, 16 K prolactin,.... The recent development of mice deficient for one gene involved during angiogenesis gives a new insight into the molecular mechanisms regulating this process. It leads to the identification of plasminogen activator inhibitor-1 or PAI-1 as a new target for tumor treatment. Although, PAI-1 is very attractive as a target for new therapeutic strategies, a better understanding of its mechanism of action is needed urgently.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Language :
French
Title :
Les aspects precliniques des therapeutiques anti-angiogenes
Alternative titles :
[en] Preclinical Features of Anti-Angiogenesis Therapy
NOËL A., GILLES C., BAJOU K., DEVY L., KEBERS F.,LEWALLE J.M., MAQUOI E., MUNAUT C., REMACLE A., FOIDART J.M. - Emerging roles for proteinases in cancer. Invasion Metastasis, 1997, 17, 221-239.
NOËL A., KEBERS F., MAQUOI E., FOIDART J.M. - Cell-cell and cell-matrix interactions during breast cancer progression. Curr. Top. Pathol., 1999, 93, 183-193.
HANAHAN D., FOLKMAN J. - Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86, 353-364.
FOLKMAN J. - Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev., 1990, 9, 171-174.
GASPARINI G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 1999, 58, 17-38.
BROOKS P.C. - Role of integrins in angiogenesis. Eur. J. Cancer, 1996, 32A, 2423-2429.
CARMELIET P., COLLEN D. - Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr. Top. Microbiol. Immunol., 1999, 237, 133-158.
O'REILLY M.S., BOEHM T., SHING Y., FUKAI N., VASIOS G., LANE W.S., FLYNN E., BIRKHEAD J.R., OLSEN B.R., FOLKMAN J. Endostatin : an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997, 88, 277-285.
O'REILLY M.S. Angiostatin : an endogenous inhibitor of angiogenesis and of tumor growth. EXS, 1997, 79, 273-294.
ANDREASEN P.A., KJOLLER L., CHRISTENSEN L., DUFFY M.J. The urokinase-type plasminogen activator system in cancer metastasis : a review. Int. J. Cancer, 1997, 72, 1-22.
LOSKUTOFF D.J., CURRIDEN S.A., HU G., DENG G. - Regulation of cell adhesion by PAI-I. APMIS, 1999, 107, 54-61.
BROOKS P.C., STROMBLAD S., KLEMKE R., VISSCHER D., SARKAR F.H., CHERESH D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest, 1995, 96, 1815-1822.
BROOKS P.C., MONTGOMERY A.M., ROSENFELD M., REISFELD R.A., HU T., KLIER G., CHERESH D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79, 1157-1164.
ISNER J.M., ASAHARA T. - Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 1999, 103, 1231-1236.
CARMELIET P., FERREIRA V., BREIER G., POLLEFEYT S., KIECKENS L., GERTSENSTEIN M., FAHRIG M., VANDENHOECK A., HARPAL K., EBERHARDT C., DECLERCQ C., PAWLING J., MOONS L., COLLEN D., RISAU W., NAGY A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996, 380, 435-439.
BAJOU K., NOËL A., GERARD R.D., MASSON V., BRUNNER N., HOLST-HANSEN C., SKOBE M., FUSENIG N.E., CARMELIET P., COLLEN D., FOIDART J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 1998, 4, 923-928.
PEDERSEN A.N., BRUNNER N., HOYER-HANSEN G., HAMER P., JAROSZ D., LARSEN B., NIELSEN H.J., STEPHENS R.W. Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients. Clin. Chem., 1999, 45, 1206-1213.
PEDERSEN H., BRUNNER N., FRANCIS D., OSTERLIND K., RONNE E., HANSEN H.H., DANO K., GRONDAHL-HANSKN J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 1994, 54, 4671-4675.
PEDERSEN H., GRONDAHL-HANSEN J., FRANCIS D., OSTERLIND K., HANSEN H.H., DANO K., BRUNNER N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 1994, 54, 120-123.
MURPHY G., GAVRILOVIC J. - Proteolysis and cell migration : creating a path? Curr Opin. Cell Biol., 1999, 11, 614-621.
PEPPER M.S., MONTESANO R. - Proteolytic balance and capillary morphogenesis. Cell Differ. Dev., 1990, 32, 319-327.
MONTESANO R., PEPPER M.S., MOHLE-STEINLEIN U., RISAU W., WAGNER E.F., ORCI L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 1990, 62, 435-445.
